Circulating C-Terminal Agrin Fragment (CAF22)
Current understanding
[human-observational] A systematic review and meta-analysis covering 21 studies and over 3,000 individuals associates higher circulating CAF22 with slower gait speed and lower Short Physical Performance Battery (SPPB) scores in healthy older adults and clinical cohorts. [human-observational] These associations support CAF22 as a candidate functional-impairment biomarker but do not establish prospective prediction of decline, specificity for neuromuscular junction deterioration, or test–retest and cross-assay reliability. [human-observational] The supplied synthesis does not establish intervention responsiveness, independent validation of a consumer test, or that lowering CAF22 improves function or reverses aging.